Citation

Carmassi C, Pardini F, Dell'Oste V, Cordone A, Pedrinelli V, Simoncini M, Dell'Osso L. Case Rep. Psychiatry 2021; 2021.

Copyright

(Copyright © 2021, Hindawi Publishing)

DOI

10.1155/2021/5547649

PMID

unavailable

Abstract

PURPOSE. Tamoxifen is a selective estrogenic receptor modulator (SERM) drug. In addition to its common use in breast cancer ER+, Tamoxifen has been object of growing interest in psychiatry as antimanic drug. At the same time, clinical concerns about Tamoxifen's depressogenic effect have been repeatedly raised even without reaching univocal conclusions. We discuss the case of a 45-year-old-male with a diagnosis of Bipolar Disorder type II, treated with Tamoxifen as relapse prevention treatment after surgery for a ER+/HER2+ breast cancer. The patient required two psychiatric admissions in a few-month time span since he showed a progressive worsening of both depressive and anxiety symptoms, with the onset of delusional ideas of hopelessness and failure up to suicidal thoughts. The clinical picture showed poor response to treatment trials based on various associations of mood-stabilising, antidepressants, and antipsychotic drugs. During the second hospitalization, after a multidisciplinary evaluation, the oncologists agreed on Tamoxifen discontinuation upon the severity of the psychiatric condition. The patient underwent a close oncological and psychiatric follow-up during the following 12 months.

METHODS. Psychiatric assessments included the Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Depression Scale (HAM-D), the Columbia Suicide Severity Rating Scale (C-SSRS), and the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF). All questionnaires were administered at the time of the second hospitalization and in a one-year follow-up.

RESULTS. Suicidal ideation fully remitted and depressive symptoms markedly and rapidly improved in the aftermath of Tamoxifen discontinuation. The symptomatological improvement remained stable across one-year follow-up.

CONCLUSIONS. Male patients with a mood disorder history constitute a high-risk group as to Tamoxifen psychiatric side effects. The onset or worsening of depressive symptoms or suicidality should be carefully addressed and promptly treated, and clinicians should be encouraged to consider the possibility of discontinue or reduce Tamoxifen therapy after a multidisciplinary evaluation. Copyright © 2021 Claudia Carmassi et al. This is an open access article distributed under the Creative Commons Attribution License

Language: en

Keywords

adult; human; male; case report; bipolar disorder; insomnia; suicidal ideation; major depression; mood disorder; clinical article; citalopram; fluoxetine; paroxetine; sertraline; trimipramine; tamoxifen; quetiapine; disease course; middle aged; anxiety disorder; panic; psychopharmacotherapy; benzodiazepine derivative; olanzapine; valproate semisodium; cancer surgery; drug withdrawal; irritability; hypomania; duloxetine; escitalopram; maintenance therapy; adjuvant chemotherapy; disease duration; cancer recurrence; add on therapy; drug dose reduction; breast surgery; Montgomery Asberg Depression Rating Scale; Article; hospital readmission; drug substitution; Hamilton Depression Rating Scale; lithium sulfate; Quality of Life Enjoyment and Satisfaction Questionnaire Short Form; delorazepam; quality of life assessment; cognitive rumination; cancer hormone therapy; estrogen receptor positive breast cancer; human epidermal growth factor receptor 2 positive breast cancer; male breast cancer